BioSpace News Archive

Live presentation and webcast to be held on November 16th at 9:00 a.m. EST

Grant to offset the cost of dental services for approximately 1,500 of the health center’s patients.

New systems include features recently launched with the award-winning 650T and 655T models

VPOR Discusses Positive Effect Of U.S. Government Reclassifying CBD Enhanced Products From Schedule 1 to Schedule 3; Pending International Distribution Deals

QMS, Master Control will help to ensure consistent document tracking and training across all BioIVT sites and support the company’s rapid growth

Tolero Pharmaceuticals a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been enrolled in a Phase 1b/2 study, Zella 102, evaluating the investigational agent alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor, plus decitabine in patients with myelodysplastic syndromes (MDS).

Scott Partridge, former vice president of global strategy for Monsanto, now part of Bayer, has been named the company’s U.S. General Counsel.

Quotient Sciences announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa.

The Green Organic Dutchman Holdings Ltd. is pleased to announce it has received its medical sales license from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations for its Ancaster, Ontario facility.

Kala Pharmaceuticals (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease.